Last update 01 Nov 2024

Ulcerative esophagitis

Last update 01 Nov 2024

Basic Info

Synonyms

Esophagitis ulcerative, Oesophagitis ulcerative, Ulcerative esophagitis

+ [8]

Introduction-

Drugs associated with Ulcerative esophagitis

Nizatidine

Target

H2 receptor

Mechanism

H2 receptor antagonists

Active Org.

Arrow Pharmaceuticals Pty Ltd.Startup [+2]

Originator Org.

Eli Lilly & Co.

Active Indication

Erosive esophagitis [+6]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date12 Apr 1988

100 Clinical Results associated with Ulcerative esophagitis

100 Translational Medicine associated with Ulcerative esophagitis

0 Patents (Medical) associated with Ulcerative esophagitis

198

Literatures (Medical) associated with Ulcerative esophagitis

11 Apr 2024·Cureus

Doxycycline-Associated Ulcerative Esophagitis: A Report of a Rare Case

Author: Panda, Suman ; Priyadarshi, Kunal ; Yadav, Dheeraj ; Nafe, Zaid ; Ranjan, Amiya

This study addresses the risks of medication-induced esophageal injury through a case presentation of a 30-year-old patient treated with doxycycline. The case highlights the importance of proper medication administration and the role of endoscopic evaluation in diagnosis and management. The broader discussion emphasizes the prevalence of such injuries, especially with antibiotics, and factors influencing their occurrence. A clinical study illustrates the corrosive effect of tetracycline, highlighting the role of pH and hyperosmolar properties. The study concludes with a reminder of the critical role of healthcare professionals in recognizing and managing medication-induced esophagitis, with endoscopy as a key diagnostic tool.

01 Dec 2023·The Lancet Gastroenterology & Hepatology

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Article

Author: Sheikh, Muhammed Y ; Cheng, Andrew ; Abrams, Gary A ; Tillman, Erik J ; Behling, Cynthia ; Bedossa, Pierre ; Sanchez, William ; Chan, Doreen ; Shringarpure, Reshma ; Rolph, Timothy ; Fong, Erica ; de Temple, Brittany ; Harrison, Stephen A ; Lucas, K Jean ; Shao, Lan ; Gogia, Sudhanshu ; Neff, Guy ; Frias, Juan P ; Yale, Kitty

BACKGROUNDFibroblast growth factor 21 (FGF21) regulates metabolism and protects cells against stress. Efruxifermin is a bivalent Fc-FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its efficacy and safety in patients with non-alcoholic steatohepatitis (NASH) and moderate (F2) or severe (F3) fibrosis.METHODSHARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA. Adults with biopsy-confirmed NASH, defined by a non-alcoholic fatty liver disease activity score (NAS) of 4 or higher and scores of 1 or higher in each of steatosis, ballooning, and lobular inflammation, with histological stage F2 or F3 fibrosis, were randomly assigned (1:1:1), via an interactive response system, to receive placebo or efruxifermin (28 mg or 50 mg), subcutaneously once weekly. Patients, investigators, pathologists, site staff, and the sponsor were masked to group assignments during the study. The primary endpoint was the proportion of patients with improvement in fibrosis of at least 1 stage and no worsening of NASH, based on analyses of baseline and week 24 biopsies (liver biopsy analysis set [LBAS]). A sensitivity analysis evaluated the endpoint in the full analysis set (FAS), for which patients with missing biopsies were considered non-responders. This trial is registered with ClinicalTrials.gov, NCT04767529, and is ongoing.FINDINGSBetween March 22, 2021, and Feb 7, 2022, 747 patients were assessed for eligibility and 128 patients (mean age 54·7 years [SD 10·4]; 79 [62%] female and 49 male [38%]; 118 [92%] white; and 56 [41%] Hispanic or Latino) were enrolled and randomly assigned to receive placebo (n=43), efruxifermin 28 mg (n=42; two randomised patients were not dosed because of an administrative error), or efruxifermin 50 mg (n=43). In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1-4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0-5·0]; p=0·036). Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0-4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8-4·3]; p=0·123). The most frequent efruxifermin-related adverse events were diarrhoea (16 [40%] of 40 patients in the efruxifermin 28 mg group and 17 [40%] of 43 patients in efruxifermin 50 mg group vs eight [19%] of 43 patients in the placebo group; all events except one were grade 1-2) and nausea (11 [28%] patients in the efruxifermin 28 mg group and 18 [42%] patients in the efruxifermin 50 mg group vs ten [23%] patients in the placebo group; all grade 1-2). Five patients (two in the 28 mg group and three in the 50 mg group) discontinued due to adverse events. Serious adverse events occurred in four patients in the 50 mg group; one was defined as drug related (ulcerative esophagitis in a participant with a history of gastro-oesophageal reflux disease). No deaths occurred.INTERPRETATIONEfruxifermin improved liver fibrosis and resolved NASH over 24 weeks in patients with F2 or F3 fibrosis, with acceptable tolerability, supporting further assessment in phase 3 trials.FUNDINGAkero Therapeutics.

01 Dec 2023·Clinical Nuclear Medicine

Elevated FAPI Activity in Ulcerative Fungal Esophagitis

Article

Author: Tang, Wenxin ; Liu, Huipan ; Xie, Yang ; Chen, Yue

AbstractWe report a case of ulcerative fungal esophagitis with elevated activity of 18F-FDG and 68Ga-FAPI (fibroblast-activating protein inhibitor). Our findings suggest that ulcerative fungal esophagitis should be considered in the differential diagnosis of cancer-like esophageal mass with increased 68Ga-FAPI uptake.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ulcerative esophagitis

Basic Info

Related

Analysis